US Patent Granted for ImmXcyte Technology

US Patent Granted for Batu Biologics Cancer Immunotherapeutic Product ImmXcyteTM

Cancer Angiogenesis Immunology Company Granted Composition of Matter Patent on Universal Immune Stimulatory Peptide

Batu Biologics announced the issuance of United States patent # 8,999,349 covering composition of matter claims for its ImmXcyteTM immune-oncology peptide technology.

Read the full article at